logo
Plus   Neg
Share
Email

Roche Reports Positive Data From OCREVUS Phase III Open-label Extension Studies

Roche (RHHBY.PK) said data from three phase III open-label extension studies demonstrated that patients who were treated with OCREVUS for six years or more had reduced risk of disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis. The company said the results show earlier treatment with OCREVUS reduced the risk of disability progression and the effect was sustained over time.

OCREVUS is the first and only therapy approved for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines has announced that tickets for the Bombardier CRJ-550 will be available for purchase starting Saturday, October 12 for travel beginning Sunday, October 27. United Airlines also revealed the first 15 routes for the new Bombardier CRJ-550 aircraft. Initially, the CRJ-550 will fly out... Coffee retail giant Starbucks (SBUX) announced its plan to expand its profit-sharing Community Store program in Korea. The company plans to open the first of several locations in early 2020. The country is one of three Starbucks markets with Community Stores, according to a press release. Starbucks... Toyota Motor Corp. has unveiled the second-generation of its hydrogen fuel-cell car, the Mirai, saying it expects the new sedan will help it to realize the goal of a hydrogen energy society. The new Mirai will seat one more than the current model and also features a fully-redesigned fuel cell system that offers up to a 30 percent increase in driving range.
Follow RTT
>